5244042025-07-012025-09-305244042025-09-305244042025-03-315244042025-04-012025-09-305244042025-07-012025-09-30in-capmkt:OtherExpenses1Member5244042025-04-012025-09-30in-capmkt:OtherExpenses1Member5244042025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026MARKSANS PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-11-132025-10-23INRMillionsQuarterlySecond quarterSingle segmentPharmaceutical Formulation2025-11-1317:40:002025-11-1318:40:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated7204090000215720000741981000022772000001061410000-25270000010380300005815000026916000016352200006086470000133334000001333340000358570000-16620000341950000099139000000009913900003646700001356060000982500000889000013361900001987000045316000012.172.17002.172.17NOTES TO CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF <BR> YEAR ENDED 30 SEPTEMBER 2025 <BR> <BR> 1. The consolidated unaudited financial results for the quarter and half year ended 30 September 2025 <BR> of Marksans Pharma Limited ('the Company' or 'the holding company') and its subsidiaries <BR> (collectively referred as 'the group') were reviewed by the Audit Committee and approved by the <BR> Board of Directors at their respective meeting held on 13 November 2025. The Statutory Auditors of <BR> the Company have carried out limited review on the above results in terms of Regulation 33 of the <BR> SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as <BR> <BR> 2. The consolidated unaudited financial results of the Company have been prepared in accordance <BR> with the recognition and measurement principles laid down in the Indian Accounting Standard 34 <BR> ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with <BR> relevant rules issued thereunder and other recognised accounting principles generally accepted in <BR> India and in terms of the Regulation. <BR> <BR> 3. The group operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS <BR> 108 on 'Operating Segments'. <BR> <BR> 4. Other income (net) includes the following net foreign exchange differences, including forward contracts: <BR> <BR> Description Quarter ended Half year ended Year Ended <BR> 30-Sep-25 30-Jun-25 30-Sep-24 30-Sep-25 30-Sep-24 31-Mar-25 <BR> <BR> Net gain / (loss) 175.10 (37.73) (122.49) 137.37 (96.38) 194.80 <BR> <BR> 5. During half year ended 30 September 2025, the Board of Directors and Shareholders of the <BR> Company have approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the <BR> employees of the Company and its subsidiary companies comprising of equity shares of the <BR> Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said <BR> Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 <BR> September 2025 to the eligible employees of the group.2025-04-012025-09-30UnauditedConsolidated134039800002721300001367611000042041400002776880000-12769900002021880000118800000500170000323191000011576790000209932000002099320000554650000-287400005259100000157341000000001573410000102996000026033700001565670000774000025723900003098000045316000013.453.45003.453.45Other Expenses1635220000Other Expenses323191000091615700006971000043433000054378000039759000000364600003646000023464000010878080000955178000078300006031110000481615000018490000000402200001274431000024819000099807000023542350000344204300004531600002642706000026880220000255680000271359000000266191000026619100006306000013200000273817000023375000021010000282714000028481500007789700003860870000385880000153200002842900004546360000728453000034420430000118800000-638190000-3439500000-117100002150000-760000-51000000-1223200000-9063000005001700000-6700002240000233600000-16007000001246600000763900000-47000001233200000-652100000144722000000069536000007518600000000000026200007318900000000000000000000001287800000235720000-364770000000000000-29000001549800003625300001416000000-528770000-141680000-30000-14171000049578600004816150000Remeasurements of the net defined benefit liabilities/assets-1000000-1000000Remeasurements of the net defined benefit liabilities/assets-2010000-2010000-260000-510000Foreign Currency Translation Reserve365410000365410000Foreign Currency Translation Reserve10314600001031460000003646700001029960000UnauditedtrueMSKA & Associatestrue2027-07-31